- Company to Host Conference Call and Webcast on Monday, June 16,
2014 -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2014--
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of
cancer metabolism and inborn errors of metabolism (IEMs), today
announced that new clinical data from the Phase 1 study of AG-221, an
orally available, selective, potent inhibitor of the mutated IDH2
protein, will be highlighted in an oral presentation at the 19thCongress of the European Hematology Association (EHA) taking place June
12 -15, 2014 in Milan, Italy.
“We look forward to sharing these new clinical data with the medical
community during the late-breaker session at EHA,” said David Schenkein,
M.D., chief executive officer of Agios. “The data build upon the AG-221
preliminary results we presented last month at the American Association
for Cancer Research (AACR) Annual Meeting, and include additional
patients from existing and new dose cohorts.”
Title: A Phase I Study of AG-221, a First
in Class, Potent Inhibitor of the IDH2-Mutant Protein, in Patients with
IDH2 Mutant Positive Advanced Hematologic Malignancies
Presentation time: Saturday, June 14 at
1:30 p.m. CEST
Session title: Late breaking1
Presenter: Stephane De Botton, M.D.,
Institut de Cancerologie Gustave Roussy, Villejuif, France
Abstract code: LB2434
Conference Call Information
Agios will host a conference call and webcast on Monday, June 16, 2014,
at 8:30 a.m. EDT to review the clinical data presented at EHA from the
ongoing Phase 1 study of AG-221. To participate in the conference call,
please dial 1-877-377-7098 (domestic) or 1-631-291-4547 (international)
and refer to conference ID 49387254. A replay of the call will be
available approximately two hours after the conclusion of the call and
will be accessible through June 23, 2014. To access the replay, please
dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and
provide the access code 49387254. The webcast can be accessed live or in
archived form under "Events & Presentations" in the Investors and Media
section of the company's website at www.agios.com.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel
drugs to treat cancer and inborn errors of metabolism, or IEMs, which
are rare genetic metabolic diseases, through scientific leadership in
the field of cellular metabolism. In addition to an active research and
discovery pipeline across both therapeutic areas, Agios has multiple
first-in-class lead product candidates in cancer metabolism and IEMs in
clinical and/or preclinical development. All Agios programs focus on
genetically identified patient populations, leveraging our knowledge of
metabolism, biology and genomics. For more information, please visit our
website at www.agios.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding the benefit of its
strategic plans and focus. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“would” and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or results
to differ materially from Agios’ current expectations and beliefs. For
example, there can be no guarantee that any product candidate Agios is
developing will successfully commence or complete necessary preclinical
and clinical development phases, or that development of any of Agios’
product candidates will successfully continue. There can be no guarantee
that any positive developments in Agios’ business will result in stock
price appreciation. Management’s expectations and, therefore, any
forward-looking statements in this press release could also be affected
by risks and uncertainties relating to a number of other important
factors, including: Agios’ results of clinical trials and preclinical
studies, including subsequent analysis of existing data and new data
received from ongoing and future studies; the content and timing of
decisions made by the U.S. FDA and other regulatory authorities,
investigational review boards at clinical trial sites and publication
review bodies; Agios’ ability to obtain and maintain requisite
regulatory approvals and to enroll patients in its planned clinical
trials; unplanned cash requirements and expenditures; competitive
factors; Agios’ ability to obtain, maintain and enforce patent and other
intellectual property protection for any product candidates it is
developing; Agios’ ability to maintain key collaborations, such as its
agreement with Celgene; and general economic and market conditions.
These and other risks are described in greater detail under the caption
“Risk Factors” included in Agios’ Quarterly Report on Form 10-Q for the
quarter ended March 31, 2014, and other filings that Agios may make with
the Securities and Exchange Commission in the future. Any
forward-looking statements contained in this press release speak only as
of the date hereof, and Agios expressly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Source: Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Lora Pike, 617-649-8608
lora.pike@agios.com
